Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
NewsYour gut might be quietly working against your brain. Researchers at UW-Madison have identified a molecule called imidazole propionate (ImP), produced by gut bacteria, that's linked to higher Alzheimer's risk, harmful protein buildup in the brain, and faster cognitive decline. The discovery opens the door to a potential new treatment strategy — think statins, but for dementia risk.
Scientists at the University of Wisconsin-Madison have identified a gut-derived molecule — imidazole propionate (ImP) — that may significantly raise Alzheimer's risk. Produced by certain gut bacteria as they break down histidine (an essential amino acid found in protein-rich foods), ImP can enter the bloodstream and travel to the brain. In mouse studies, elevated ImP levels increased the buildup of beta-amyloid and tau proteins — the hallmark signs of Alzheimer's disease — ultimately leading to neuron death.
The findings, published in Nature Communications, were further validated in nearly 1,200 human participants. Those with higher blood ImP levels showed more biological markers of dementia and experienced significantly faster cognitive decline over time.
By the Numbers:
Why it matters: This research gives scientists a precise, measurable target — ImP — to potentially intervene in Alzheimer's progression. The researchers envision a drug that lowers ImP levels in the blood, much like statins lower cholesterol to reduce heart disease risk, which could meaningfully slow or prevent dementia for a large portion of the population.
